Tissue plasminogen activator for the treatment of parapneumonic effusions in pediatric patients

Area of Science:

• Pulmonology
• Pediatric Medicine
• Pharmacology

Background:

• Intrapleural fibrinolysis has a long history in treating pleural effusions.
• Complicated pleural effusions often feature fibrin and loculations, hindering drainage.
• Tissue plasminogen activator (tPA) has largely replaced older agents like urokinase and streptokinase due to improved safety and availability.

Purpose of the Study:

• To review the pathophysiology, diagnosis, and treatment of parapneumonic effusion and empyema.
• To focus on the role of intrapleural fibrinolysis, specifically tPA, in pediatric patients.
• To evaluate the current evidence supporting tPA use in children for pleural effusion management.

Main Methods:

• Review of existing literature on intrapleural fibrinolytic therapy.
• Analysis of studies investigating tPA efficacy in pediatric populations.
• Discussion of parapneumonic effusion and empyema management strategies.

Main Results:

• tPA is supported by literature for treating pleural effusions in adults and is a standard approach.
• Recent data indicate tPA is effective for pediatric pleural effusions and empyema.
• Intrapleural fibrinolysis is a viable alternative to surgical intervention in children.

Conclusions:

• tPA is a recommended treatment for pediatric pleural effusions and empyema.
• Evidence supports fibrinolytic therapy as a less invasive option than surgery for children.
• Further research is needed to address study heterogeneity and refine pediatric treatment protocols.